- What is the current status of Immune Pharmaceuticals?
- Immune Pharmaceuticals is currently inactive and ceased to operate in March 2020.
- What is Immune Pharmaceuticals' primary focus?
- Immune Pharmaceuticals is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, with a lead product, bertilimumab, for cancer and inflammatory diseases.
- What is bertilimumab and what does it target?
- Bertilimumab is Immune Pharmaceuticals' lead product, a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine involved in immune responses and eosinophil attraction to inflammation sites.
- What clinical trials is Immune Pharmaceuticals conducting for bertilimumab?
- Immune Pharmaceuticals is conducting two phase-2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis.
- When was Immune Pharmaceuticals founded?
- Immune Pharmaceuticals was founded in July 2010.
- How many employees does Immune Pharmaceuticals have?
- Immune Pharmaceuticals has 1-10 employees.
- What is the total amount of funding raised by Immune Pharmaceuticals?
- Immune Pharmaceuticals has raised a total of $52,700,000.
- When was Immune Pharmaceuticals' last funding round and who were the investors?
- Immune Pharmaceuticals' last funding round was in July 2015, with investments from Discover Growth Fund and Melini Capital.
- Where is Immune Pharmaceuticals headquartered?
- Immune Pharmaceuticals is headquartered in Jerusalem, Israel.
